Faculty of Environment & Life, Beijing University of Technology, Beijing 100124, China.
Department of Pharmacy, COMSATS University Islamabad, Abbottabad Campus, Abbottabad 22060, Pakistan.
Drug Discov Today. 2022 Aug;27(8):2244-2251. doi: 10.1016/j.drudis.2022.03.016. Epub 2022 Mar 26.
Recombinant virus-based transgene therapy has shown promising results in solid tumors. Oncolytic virotherapy is a research hotspot because of its additional immunostimulatory effects. However, metastatic malignancies require systemic virotherapy, which necessitates the use of safe and effective vehicles for drug delivery. Mesenchymal stem cells (MSCs) are good carriers because of their tumor-tropic and immune-evasive capabilities. We collated published results from pre-clinical and clinical trials to support the use of MSCs as Trojan horses for the systemic administration of recombinant viruses, with a focus on glioblastoma. The generation of modified MSCs harboring recombinant viruses could expedite bench-to-bedside transformation.
基于重组病毒的转基因治疗在实体瘤中显示出良好的效果。溶瘤病毒治疗因其额外的免疫刺激作用而成为研究热点。然而，转移性恶性肿瘤需要系统的病毒治疗，这就需要使用安全有效的药物输送载体。间充质干细胞（MSCs）因其具有肿瘤趋向性和免疫逃避能力而成为良好的载体。我们汇集了临床前和临床试验的已发表结果，以支持将 MSCs 作为携带重组病毒的特洛伊木马用于全身给药，重点是神经胶质瘤。生成携带重组病毒的改良 MSCs 可以加速从实验室到临床的转化。
